HK Stock Market Move | NIO-SW (09866) increases by more than 6% for the first time, expected to have a single quarter profit for the first time, with an estimated adjusted operating profit of up to 1.2 billion yuan for the last quarter.
NIO-SW (09866) rose more than 6%, as of the press time, up 6.07% to HK$38.76, with a turnover of HK$77.05 million.
NIO-SW (09866) rose by more than 6%, as of the time of writing, it is up by 6.07%, trading at 38.76 Hong Kong dollars, with a turnover of 77.05 million Hong Kong dollars.
On the news front, on February 5th, NIO released a profit forecast for the fourth quarter of 2025, expecting the company to achieve adjusted operating profit (non-GAAP) of between RMB 700 million (approximately USD 100 million) and RMB 1.2 billion (approximately USD 172 million) in the fourth quarter of 2025.
It is reported that this is the first time that NIO has recorded a single quarter of adjusted operating profit (non-GAAP) since its founding 11 years ago. Explaining the reason for the expected profitability in 2025, NIO mentioned that this is mainly due to the continuous sales growth in the fourth quarter of 2025, favorable product mix driving the optimization of automotive gross margin, and the company's continued implementation of comprehensive cost reduction and efficiency improvement measures.
Related Articles

HK Stock Market Move | VOICECOMM(02495) rose more than 10% in early trading, with the company recently winning a large contract worth 300 million yuan in the "AI+ elderly care" sector.

HK Stock Market Move | CALB(03931) rose more than 3% with January commercial battery delivery volume up 630% year-on-year, the company plans to implement full circulation of H shares.

Goldman Sachs: INNOVENT BIO (01801) had strong product sales last year, with a target price of HKD 102.85.
HK Stock Market Move | VOICECOMM(02495) rose more than 10% in early trading, with the company recently winning a large contract worth 300 million yuan in the "AI+ elderly care" sector.

HK Stock Market Move | CALB(03931) rose more than 3% with January commercial battery delivery volume up 630% year-on-year, the company plans to implement full circulation of H shares.

Goldman Sachs: INNOVENT BIO (01801) had strong product sales last year, with a target price of HKD 102.85.






